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Background: Osteosarcoma is the most common type of bone cancer and is notorious for its rapid progression.
The Notch signaling pathway has recently been shown to be involved in osteosarcoma. As a major sheddase of
Notch receptors, ADAM10 has been implicated in many types of cancers, but its role in osteosarcoma has not been
investigated. Previous studies have shown that the expression of CD31 was significantly elevated in metastatic
osteosarcoma; however, its expression in nonmetastatic groups is not known. In addition, the mysterious
multinucleated giant cell in giant cell-rich osteosarcoma was previously regarded as an osteoclast-like cell, but its
exact identity is unclear.
Method: Tissue chip samples from 40 cases of nonmetastatic osteosarcoma were stained for cytoplasmic ADAM10,
activated Notch1 and CD31. Osteoclasts in tumor sections were also stained for tartrate-resistant acid phosphatase
(TRAP).
Results: Immunofluorescence staining revealed that ADAM10 expression significantly increased with the
progression of osteosarcoma as well as in osteoblastic osteosarcoma, whereas the expression of the Notch
intracellular domain (NICD) and CD31 was not significantly altered between different pathological stages. In
addition, multinucleated giant cells in giant cell-rich osteosarcoma were also found to coexpress CD31, ADAM10
and NICD, but were negative for TRAP staining.
Conclusions: Our results highlight the importance of ADAM10 in the progression of osteosarcoma and suggest
that the protein might be a potential therapeutic target in osteosarcoma treatment. This study also demonstrates
that the multinucleated giant cell is an angiogenic tumor cell, rather than an osteoclast, and involves ADAM10/
Notch1 signaling activation.
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Osteosarcoma, the most common type of primary bone
cancer, is a malignant neoplasm notorious for its high
aggressiveness and early metastatic potential [1]. How-
ever, little is known about the signaling pathways that
are crucial for its progression, and the molecular biology
of osteosarcoma remains poorly understood. Histologi-
cally, osteosarcoma is categorized into several different
types, including osteoblastic osteosarcoma, chondroblas-
tic osteosarcoma, fibroblastic osteosarcoma and giant* Correspondence: nibingxi@yahoo.com; trauma2@163.com
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unless otherwise stated.cell-rich osteosarcoma. The giant cell-rich osteosarcoma
is the rare subtype of primary osteogenic sarcoma, and,
to the best of our knowledge, only 18 cases have been
reported in the literature to date [2]. Its name derives
from the existence of multinucleated giant cells within
the tumor tissues, which were generally believed to be
osteoclast-like tumor cells [2]; yet their exact identity
still remains to be elucidated.
A class of disintegrins and metallproteinases, known
as ADAMs, have been shown to participate in a variety
of signaling events that are aberrant in cancers as well as
during tumor progression [3]. ADAM10, a member of
the ADAM family, has been found to be upregulated in
many cancers, including ovarian, colon and prostate
cancers [4,5]. Overexpression of ADAM10 promotes thetd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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cinomas, whereas downregulation of its expression re-
duces proliferation of carcinoma cells [6,7]. However,
the role of ADAM10 in osteosarcoma is still unclear.
As a membrane-bound sheddase, ADAM10 cleaves a var-
iety of cell surface proteins, including Notch receptors [8,9].
In the canonical Notch signaling pathway, Notch receptors
interact with membrane-anchored ligands, followed by se-
quential proteolytic cleavage by ADAM10 and presenilin
within the transmembrane, thus releasing the Notch in-
tracellular domain (NICD), which enters the nucleus and
regulates a cohort of Notch-dependent genes. Although ab-
errant Notch receptor expression has been reported in
osteosarcoma [10] and manipulation of the Notch pathway
has been shown to play a crucial role for Hes1 (a Notch-
dependent gene) in osteosarcoma invasion and metastasis
[11,12], whether the ADAM10–Notch1 signaling axis is
particularly involved in osteosarcoma is unknown.
CD31 is a member of the immunoglobulin (Ig) gene
superfamily and plays an important role in a number of
endothelial cell functions, including angiogenesis, in-
flammation, integrin activation and intercellular adhesion
[13-15], which could also be employed by tumor cells for
their progression. Indeed, on the basis of their immuno-
histochemical staining of primary and metastatic osteosar-
coma samples, Arihiro et al. suggested that the formation
of metastatic foci of osteosarcoma cells in other bones
might be regulated by CD31 to promote endothelial cell
migration [16]. Nevertheless, the role of CD31 in nonme-
tastatic osteosarcoma has not yet been revealed.
The goal of our present study was to investigate the
expression of ADAM10, Notch1, CD31 and tartrate-
resistant acid phosphatase (TRAP) in nonmetastatic




Paraformaldehyde-fixed, paraffin-embedded human osteo-
sarcoma tissue chip slides were purchased from US
Biomax (Rockville, MD, USA). Each slide contained 40
duplicate samples of osteosarcoma tissues, and patho-
logical stages included IA (n = 3), IB (n = 5), IIA (n = 10)
and IIB (n = 22), according to the Musculoskeletal Tumor
Society Staging System. This study was approved by the
ethics committee of Daping Hospital of the Third Military
Medical University.
Reagents and antibodies
Mouse anti-human CD31 monoclonal antibody (Ab), rabbit
anti-human ADAM10 (cytoplasmic domain) polyclonal
Ab and rabbit anti-human activated Notch1 NICD poly-
clonal Ab were all purchased from Abcam (Cambridge,
UK). Isotype-specific control Abs were also obtained fromAbcam and were used to control staining specificity.
Fluorescein isothiocyanate (FITC)-conjugated goat anti-
mouse IgG Ab (ZSGB-BIO, Beijing, China) and cyanine
3 (Cy3)-conjugated goat anti-rabbit IgG Ab (Beyotime
Institute of Biotechnology, Jiangsu, China) were used as
secondary Abs. Antifade mounting medium was also
obtained from Beyotime Institute of Biotechnology.
Immunohistological and immunofluorescent staining
Paraffin tissue sections were deparaffinized in xylene,
rehydrated through graded ethanol series and washed
in 10 mM phosphate-buffered saline (PBS), pH 7.4. He-
matoxylin and eosin (H&E) staining was performed
according to a standard protocol. The histological types
were assessed by an experienced pathologist specializ-
ing in osteosarcoma diagnosis. For immunofluorescent
staining, antigen retrieval was performed by incubating
tissue sections for 20 minutes in 0.01 M sodium citrate
buffer, pH 6.0, and heated in a microwave oven, then
sections were permeabilized with 0.1% Triton X-100.
After blocking with 5% bovine serum albumin/PBS for
30 minutes, three sequential slides were then incubated
with anti-CD31 Ab, anti-ADAM10 (cytoplasmic domain)
Ab and anti activated Notch1 (NICD) Ab, respectively. For
double-immunofluorescence staining, two additional se-
quential slides were incubated with either anti-CD31
Ab (mouse anti-human) plus anti-ADAM10 Ab (rabbit
anti-human) or anti-CD31 Ab plus anti-NICD Ab (rabbit
anti-human), respectively. Isotype-specific control Abs
were used to test staining specificity. Slides were incu-
bated overnight at 4°C. After being washed with PBS, slides
were stained with secondary FITC anti-mouse Ab and Cy3
anti-rabbit Ab for 30 minutes at room temperature (RT).
Afterward, nuclei were stained with 4′,6-diamidino-2-phe-
nylindole (DAPI) for 10 minutes at RT. Images were ob-
tained using the MRC-600 digital confocal laser scanning
system (Bio-Rad Laboratories, Hercules, CA, USA).
TRAP/DAPI staining
TRAP staining was performed on deparaffinized and rehy-
drated sections using the Acid Phosphatase, Leukocyte
(TRAP) Kit (Sigma-Aldrich, St Louis, MO, USA) accord-
ing to the manufacturer’s instructions. DAPI staining was
performed afterward as mentioned above to visualize the
nuclei.
Data analysis
Acquired images were exported and merged using Image-
Pro Plus version 6.0 software (MediaCybernetics, Rockville,
MD, USA). NICD and CD31 density percentages were
measured as the percentage of positive FITC signal area
against the whole field area under 100× magnification as
described by Connor et al. [17]. ADAM10-positive tumor
cells were counted in ADAM10/DAPI merged images
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formed with tools in Image-Pro Plus software. Statistical
differences were determined using a two-tailed, un-
paired Student’s t-test.
Results
ADAM10 expression was significantly increased in more
advanced and osteoblastic osteosarcoma
We first examined the expression of ADAM10 in osteo-
sarcoma tissue chips. Under 400× magnification, a po-
larized and condensed expression pattern of cytoplasmicFigure 1 Increased expression of ADAM10 in higher-stage osteosarco
ADAM10 domain (red dots) merged with 4′,6-diamidino-2-phenylindole (DAP
staged from IA to IIB. Specific ADAM10 staining was controlled by using is
The lower-right graph shows statistical analysis of the number of ADAM10
disintegrin and metalloproteinase 10. Scale bar, 20 μm. *P < 0.05.ADAM10 was observed in all cases and stages of osteosar-
coma (Figure 1). In order to determine whether ADAM10
was differentially expressed among different stages of
osteosarcoma, ADM10+ tumor cells were counted under
100× ADAM10/DAPI merged images. The number of
ADM10+ tumor cells in stages IIA and IIB increased sig-
nificantly compared with those in stage IA (Figure 1), sug-
gesting that elevated ADAM10 levels in tumor cells might
be involved in the progression of osteosarcoma.
After the immunofluorescent staining, osteosarcoma
tissue chips were stained with H&E. Four types ofma tissue. The panels show representative images of the cytoplasmic
I)-stained nuclei (blue) taken from osteosarcoma tissues pathologically
otype-specific control antibody (control immunoglobulin G (IgG)).
+ tumor cells in osteosarcoma tissues at different stages. ADAM10: A
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rich osteosarcoma, osteoblastic osteosarcoma, fibro-
blastic osteosarcoma and chondroblastic osteosarcoma
(Additional file 1: Figure S1, upper panels). We then
reanalyzed the number of ADAM10+ tumor cells based
on different histological types and found that osteo-
blastic osteosarcoma had significantly more ADAM10+
tumor cells compared with chondroblastic and fibro-
blastic osteosarcomas (Additional file 1: Figure S1,
lower graph), suggesting that ADAM10 might be in-
volved specifically in the pathogenesis of osteoblastic
osteosarcoma.Figure 2 Expression of activated Notch1 in different stages of osteos
domain (NICD; red) expression in stages IB, IIA and IIB osteosarcoma tissues
(control immunoglobulin G (IgG)) antibody. The lower graph shows the sta
different stages. Scale bar, 80 μm.Activated Notch1 was not markedly altered in different
stages of osteosarcoma
As ADAM10 is a major regulator of Notch signaling
via its shedding of Notch receptors [8,9], we sought to
determine whether increased expression of ADAM10
in osteosarcoma progression would also lead to in-
creased activation of Notch1. We detected the expres-
sion of activated Notch1 (NICD) in another sequential
slide. As shown in the upper panels of Figure 2, Notch1
was activated in osteosarcoma tissue at all stages; how-
ever, its activation was not significantly correlated with
pathological staging, as shown by NICD density fromarcoma. The panels show representative images of Notch intracellular
. Specific NICD staining was controlled by using isotype-specific control
tistical analysis of the density of NICD+ cells in osteosarcoma tissues at
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was activated in osteosarcoma but that its activation
might not contribute to disease progression.
CD31 might not contribute to osteosarcoma progression
Previous studies have shown that the expression of CD31
was significantly increased in metastatic osteosarcoma
compared with primary osteosarcoma [16]. However, the
differences between nonmetastatic groups are unclear.
Hence we performed FITC-CD31 staining on all osteosar-
coma tissues from stages IA to IIB. Although a trend of in-
creased CD31 expression was observed as osteosarcoma
progressed, no significant differences were found betweenFigure 3 Expression of CD31 in different stages of osteosarcoma. The
stages IA to IIB osteosarcoma tissues. Isotype-specific control antibody (con
CD31 staining. The lower-right graph shows statistical analysis of CD31dendifferent pathological stages in terms of CD31 density
(Figure 3), suggesting that vascularity (represented by the
expression of CD31) was not dramatically altered during
the pathological progression of nonmetastatic osteosar-
coma, a scenario different from metastatic groups.
Multinucleated giant cell is angiogenic tumor cell, not
osteoclast
We found that the multinucleated giant cells in giant cell-
rich osteosarcoma stained positively with CD31 (Figure 4,
left panels), suggesting their angiogenic property. More-
over, cytoplasmic ADAM10 and activated Notch1 were
colocalized within these giant cells (Figure 4), suggestingpanels show representative images of CD31 expression (green) from
trol immunoglobulin G (IgG)) was used to show the specificity of
sity in osteosarcoma tissues at different stages. Scale bar, 80 μm.
Figure 4 Expression of CD31, cytoplasmic ADAM10 and activated Notch1 in multinucleated giant cells. In giant cell-rich osteosarcoma
sections, CD31 expression was visualized with mouse anti-human monoclonal antibody (Ab), followed by fluorescein isothiocyanate (FITC)-coupled goat
anti-mouse secondary Ab (green). ADAM10 and Notch intracellular domain (NICD) expression were detected by rabbit anti-human polyclonal Abs,
respectively, and cyanine 3-coupled goat anti-rabbit secondary Ab (red). Nuclei of osteosarcoma cells were stained with 4′,6-diamidino-2-phenylindole
(DAPI). Arrowheads in the merged pictures indicate colocalization of CD31/ADAM10 and CD31/NICD in multinucleated osteosarcoma tumor cells.
Isotype-specific control immunoglobulin G (IgG) Abs were used to test staining specificity. ADAM10: A disintegrin and metalloproteinase 10. Scale
bar, 20 μm.
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giogenic tumor cells. By TRAP staining, we observed that
TRAP was absent in multinucleated cells in giant cell-rich
osteosarcoma tissue, whereas TRAP+ cells were found in
osteoblastic, fibroblastic and chondroblastic osteosarcoma
tissue (Figure 5). Taken together, these results suggest
that what were previously called osteoclast-like multi-
nucleated giant cells [2] are not osteoclasts, but rather
angiogenic tumor cells that involve ADAM10/Notch1
signaling activation.
Discussion
Although ADAM10 has been found to be upregulated in
many cancers [4,5], its expression in tumors with mesen-
chymal origin (particularly osteosarcoma) remains un-
known. Herein we show that ADAM10 was generally
expressed in osteosarcoma tumor cells in a condensed and
polarized pattern. The level of ADAM10 in tumor cells
significantly increases as osteosarcoma progresses, as well
as in osteoblastic osteosarcoma tissue, suggesting that it
might play a role in osteosarcoma tumor progression and
the pathological development of osteoblastic osteosar-
coma. As ADAM10 is a major sheddase of Notch recep-
tors [8,9], and because researchers in recent studies have
discovered that Notch signaling was activated in human
osteosarcoma and may play a role in tumor invasion
and metastasis [11,18,19], we speculate that ADAM10
might participate in osteosarcoma progression throughthe shedding of Notch receptors and activation of the
Notch signaling pathway.
Currently, there is no systematic evaluation comparing
Notch expression in clinical osteosarcoma between dif-
ferent pathological stages. Hence, we analyzed activated
Notch1 (NICD) expression from stages IB to IIB at the
protein level and found no significant alteration in NICD
density. Therefore, as one of four members in the mam-
malian Notch receptor family, Notch1 might not be the
Notch receptor responsible for osteosarcoma progression.
Similarly, Tanaka et al. found that expression of Notch1
mRNA was decreased in specimens from human osteosar-
coma biopsies compared with normal bone tissues [20].
Previous studies have shown that CD31 expression
was significantly correlated between primary and meta-
static osteosarcomas [16], but the correlation between
nonmetastatic groups is not clear. In our present study,
we found that variation in the density of CD31 was not
significantly associated with osteosarcoma staging from
IA to IIB, although there was a trend toward increased
CD31 expression as osteosarcoma progressed.
The expression of CD31 and activation of Notch1 did
not dramatically contribute to osteosarcoma progression
overall. In the specific case of multinucleated tumor cells
in giant cell-rich osteosarcoma, however, the expression of
CD31 may facilitate the adhesion of these tumor cells to
endothelial cells. Migration between endothelial cells may
also occur via homophilic interactions between CD31 and
Figure 5 TRAP/DAPI staining of various histological types of osteosarcoma. The left panels show tartrate-resistant acid phosphatase (TRAP)
staining of giant cell-rich, osteoblastic, fibroblastic and chondroblastic osteosarcomas, respectively. The right panels show 4′,6-diamidino-2-phenylindole
(DAPI) staining of the nuclei of sections identical to those on the left panels. Note that negative TRAP staining was observed in multinucleated giant
cells (upper panel). Dashed lines outline the cell contours. Scale bar, 20 μm.
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αvβ3 integrin, which has been shown to be expressed in
both osteosarcoma cells and endothelial cells [14,21,22],
thus promoting tumor cell migration. Given the fact thatthese tumor cells also coexpress ADAM10 and activated
Notch1, ADAM10/Notch1 signaling might also participate
in this process, as recent studies have demonstrated that
ADAM10 and Notch1 could promote the migration of a
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vidually [24,25]. Furthermore, the absent staining of TRAP
and positive staining of CD31 in multinucleated giant cells
suggest that these cells are not osteoclasts, but rather a
type of angiogenic tumor cells in which ADAM10/Notch1
signaling is activated.
Conclusion
In our present study, we examined the expression of CD31,
ADAM10, Notch1 and TRAP in nonmetastatic osteosar-
coma tissue chips. We found that only ADAM10 expres-
sion was significantly correlated with tumor progression
and osteoblastic osteosarcoma development. Our results
also suggest that multinucleated giant cells are not osteo-
clasts, but angiogenic tumor cells in which ADAM10/
Notch1 signaling is activated and might be implicated
in tumor cell migration. The results of this study imply
heterogeneity in osteosarcoma between metastatic and
nonmetastatic types and complexity within nonmetastatic
types. It also highlights ADAM10 as a potential target for
the biological intervention of nonmetastatic osteosarcoma.
Additional file
Additional file 1: Figure S1. Analysis of ADAM10+ cells in various
histological types of osteosarcoma. The upper panels show hematoxylin
and eosin staining of giant cell-rich, osteoblastic, fibroblastic, and
chondroblastic osteosarcoma tissue, respectively. The lower graph
shows the number of tumor cells expressing ADAM10 in chondroblastic,
fibroblastic, and osteoblastic osteosarcoma tissue. Scale bar, 20 μm. NS, not
significant *P < 0.05, ***P < 0.001.
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